Form 4: Core Laboratories Director Klingensmith Reports Stock Transactions
SEC Form 4
Director Harvey Robert Klingensmith reports acquisition and disposal of Core Laboratories Inc. common stock and restricted shares on April 1, 2024.
Summary
- On April 1, 2024, Director Harvey Robert Klingensmith engaged in transactions involving Core Laboratories Inc. (CLB) securities.
- The transactions included the acquisition of 9,317 restricted shares and the disposal of 6,419 common stock shares.
- Following these transactions, Klingensmith directly owns 32,645 common stock shares and 9,317 restricted shares.
- The restricted shares acquired will vest on April 1, 2025.
- The restricted shares disposed of vested on April 1, 2024.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the actions of company leadership.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they provide insight into the director's view of the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of stock acquisition and disposal transactions. |
| 04/01/2025 | Vesting date for the acquired restricted shares. |
| 04/02/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.